Cargando…

Facilitators and barriers for vaccination in patients with inflammatory rheumatic musculoskeletal diseases: a prospective cohort study

INTRODUCTION: To identify facilitators and barriers towards vaccination in general and specifically against pneumococci, influenza and SARS-CoV-2 in patients with rheumatic musculoskeletal diseases (RMD). METHODS: Between February and April 2021, consecutive patients with RMD were asked to complete...

Descripción completa

Detalles Bibliográficos
Autores principales: Andreica, Ioana, Roman, Iulia, Redeker, Imke, Baraliakos, Xenofon, Braun, Juergen, Kiltz, Uta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10277552/
https://www.ncbi.nlm.nih.gov/pubmed/37295840
http://dx.doi.org/10.1136/rmdopen-2022-002875
_version_ 1785060307945652224
author Andreica, Ioana
Roman, Iulia
Redeker, Imke
Baraliakos, Xenofon
Braun, Juergen
Kiltz, Uta
author_facet Andreica, Ioana
Roman, Iulia
Redeker, Imke
Baraliakos, Xenofon
Braun, Juergen
Kiltz, Uta
author_sort Andreica, Ioana
collection PubMed
description INTRODUCTION: To identify facilitators and barriers towards vaccination in general and specifically against pneumococci, influenza and SARS-CoV-2 in patients with rheumatic musculoskeletal diseases (RMD). METHODS: Between February and April 2021, consecutive patients with RMD were asked to complete a structured questionnaire on general knowledge about vaccination, personal attitudes and perceived facilitators and barriers towards vaccination. General facilitators (n=12) and barriers (n=15) and more specific ones for vaccination against pneumococci, influenza and SARS-CoV-2 were assessed. Likert scales had four response options: from 1 (completely disagree) to 4 (completely agree). Patient and disease characteristics, their vaccination records and attitudes towards vaccination against SARS-CoV-2 were assessed. RESULTS: 441 patients responded to the questionnaire. Knowledge about vaccination was decent in ≥70% of patients, but <10% of patients doubted its effectiveness. Statements on facilitators were generally more favourable than on barriers. Facilitators for SARS-CoV-2 vaccination were not different from vaccination in general. Societal and organisational facilitators were more often named than interpersonal or intrapersonal facilitators. Most patients indicated that recommendations of their healthcare professional would encourage them to be vaccinated—without preference for general practitioner or rheumatologists. There were more barriers towards SARS-CoV-2 vaccination than to vaccination in general. Intrapersonal issues were most frequently reported as a barrier. Statistically significant differences in response patterns to nearly all barriers between patients classified as definitely willing, probably willing and unwilling to receive SARS-CoV-2 vaccines were noted. DISCUSSION: Facilitators towards vaccination were more important than barriers. Most barriers against vaccination were intrapersonal issues. Societal facilitators identified support strategies in that direction.
format Online
Article
Text
id pubmed-10277552
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-102775522023-06-20 Facilitators and barriers for vaccination in patients with inflammatory rheumatic musculoskeletal diseases: a prospective cohort study Andreica, Ioana Roman, Iulia Redeker, Imke Baraliakos, Xenofon Braun, Juergen Kiltz, Uta RMD Open Infections INTRODUCTION: To identify facilitators and barriers towards vaccination in general and specifically against pneumococci, influenza and SARS-CoV-2 in patients with rheumatic musculoskeletal diseases (RMD). METHODS: Between February and April 2021, consecutive patients with RMD were asked to complete a structured questionnaire on general knowledge about vaccination, personal attitudes and perceived facilitators and barriers towards vaccination. General facilitators (n=12) and barriers (n=15) and more specific ones for vaccination against pneumococci, influenza and SARS-CoV-2 were assessed. Likert scales had four response options: from 1 (completely disagree) to 4 (completely agree). Patient and disease characteristics, their vaccination records and attitudes towards vaccination against SARS-CoV-2 were assessed. RESULTS: 441 patients responded to the questionnaire. Knowledge about vaccination was decent in ≥70% of patients, but <10% of patients doubted its effectiveness. Statements on facilitators were generally more favourable than on barriers. Facilitators for SARS-CoV-2 vaccination were not different from vaccination in general. Societal and organisational facilitators were more often named than interpersonal or intrapersonal facilitators. Most patients indicated that recommendations of their healthcare professional would encourage them to be vaccinated—without preference for general practitioner or rheumatologists. There were more barriers towards SARS-CoV-2 vaccination than to vaccination in general. Intrapersonal issues were most frequently reported as a barrier. Statistically significant differences in response patterns to nearly all barriers between patients classified as definitely willing, probably willing and unwilling to receive SARS-CoV-2 vaccines were noted. DISCUSSION: Facilitators towards vaccination were more important than barriers. Most barriers against vaccination were intrapersonal issues. Societal facilitators identified support strategies in that direction. BMJ Publishing Group 2023-06-09 /pmc/articles/PMC10277552/ /pubmed/37295840 http://dx.doi.org/10.1136/rmdopen-2022-002875 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Infections
Andreica, Ioana
Roman, Iulia
Redeker, Imke
Baraliakos, Xenofon
Braun, Juergen
Kiltz, Uta
Facilitators and barriers for vaccination in patients with inflammatory rheumatic musculoskeletal diseases: a prospective cohort study
title Facilitators and barriers for vaccination in patients with inflammatory rheumatic musculoskeletal diseases: a prospective cohort study
title_full Facilitators and barriers for vaccination in patients with inflammatory rheumatic musculoskeletal diseases: a prospective cohort study
title_fullStr Facilitators and barriers for vaccination in patients with inflammatory rheumatic musculoskeletal diseases: a prospective cohort study
title_full_unstemmed Facilitators and barriers for vaccination in patients with inflammatory rheumatic musculoskeletal diseases: a prospective cohort study
title_short Facilitators and barriers for vaccination in patients with inflammatory rheumatic musculoskeletal diseases: a prospective cohort study
title_sort facilitators and barriers for vaccination in patients with inflammatory rheumatic musculoskeletal diseases: a prospective cohort study
topic Infections
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10277552/
https://www.ncbi.nlm.nih.gov/pubmed/37295840
http://dx.doi.org/10.1136/rmdopen-2022-002875
work_keys_str_mv AT andreicaioana facilitatorsandbarriersforvaccinationinpatientswithinflammatoryrheumaticmusculoskeletaldiseasesaprospectivecohortstudy
AT romaniulia facilitatorsandbarriersforvaccinationinpatientswithinflammatoryrheumaticmusculoskeletaldiseasesaprospectivecohortstudy
AT redekerimke facilitatorsandbarriersforvaccinationinpatientswithinflammatoryrheumaticmusculoskeletaldiseasesaprospectivecohortstudy
AT baraliakosxenofon facilitatorsandbarriersforvaccinationinpatientswithinflammatoryrheumaticmusculoskeletaldiseasesaprospectivecohortstudy
AT braunjuergen facilitatorsandbarriersforvaccinationinpatientswithinflammatoryrheumaticmusculoskeletaldiseasesaprospectivecohortstudy
AT kiltzuta facilitatorsandbarriersforvaccinationinpatientswithinflammatoryrheumaticmusculoskeletaldiseasesaprospectivecohortstudy